Medicare Part D plan sponsors reimbursed pharmacies for generic drugs at excessively high rates during 2021, according to a study of reimbursement rates, which were
Point-of-sale prices for generic imatinib are substantially higher than the pharmacy acquisition costs from 2017 to 2023, a study of Medicare Part D beneficiaries shows.
A study of evidence-based medicines for 6 cardiovascular diseases (CVDs; atrial fibrillation, heart failure, hyperlipidemia, hypertension, post–acute coronary syndrome secondary prevention, and stable angina) shows
The use of the first generic maintenance inhaler approved for asthma and chronic obstructive pulmonary disease (COPD) produced outcomes similar to those with the original
“Continuation patents are becoming increasingly common in drug patent thickets, likely delaying or deterring generic competition, and thus potentially contributing to delays in patient access to
Utilization management for Medicare Part D oral oncology drugs increased between 2010 and 2020, according to a study of formulary files. “Prior authorization was the
From 2017 to 2020, inflationary rebates offset 2% to 12% of Medicaid medication spending, researchers report: “State Medicaid programs cover nearly all Food and Drug
FDA this week granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics), a RAS GTPase family inhibitor, for adult patients with KRASG12C-mutated locally advanced or metastatic